Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: A study by the Consortium for Improving Survival of Lymphoma

Consortium for Improving Survival of Lymphoma (CISL) study group

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.

Original languageEnglish
Pages (from-to)1020-1026
Number of pages7
JournalLeukemia and Lymphoma
Volume56
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Bibliographical note

Funding Information:
1Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea, 2Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea, 3Department of Hematology, Gachon University Gil Medical Center, Incheon, Korea, 4Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, 5Depatrment of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, 6Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, 7Department of Hematology and Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea, 8Hematologic Oncology Clinic, Center for Specific Organs Cancer, National Cancer Center, Goyang, Korea 9Department of Internal Medicine, Catholic University of Daegu School of Medicine, Cheonan, Korea, 10Division of Hematology-Oncology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea, 11Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea, 12Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Korea, 13Department of Hematology and Oncology, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea, 14Division of Hematology, Department of Internal Medicine, St. Vincent’s Hospital, Catholic University, Medical College, Suwon, Korea, 15Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, 16Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea, 17Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, 18Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea, 19Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea, 20Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Hallym University, Hallym University Sacred Heart Hospital, Anyang, Korea, 21Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea and 22 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Publisher Copyright:
© 2014 Informa UK, Ltd.

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: A study by the Consortium for Improving Survival of Lymphoma'. Together they form a unique fingerprint.

Cite this